1. Market Research
  2. > Pharmaceutical Market Trends
  3. > South Korea Pharmaceuticals and Healthcare Report Q1 2016

South Korea Pharmaceuticals and Healthcare Report Q1 2016

  • December 2015
  • -
  • Business Monitor International
  • -
  • 116 pages

Includes 3 FREE quarterly updates

BMI View:

South Korea's biomedical research and development sector will continue to flourish in line withgrowing investments by local drugmakers. Facilitating this commitment is the strong support provided bythe government as well as the opportunities to form drug discovery partnerships with leading US-basedcompanies. As the sector develops, the broader economy will benefit and serve to support South Korea'sexport growth.

Headline Expenditure Projections

- Pharmaceuticals: KRW16,590bn (USD15.8bn) in 2014 to KRW17,117bn (USD14.6bn) in 2015; +3.2%in local currency terms and -7.1% in US dollar terms. Forecast unchanged from previous quarter,negative growth in USD terms due to currency fluctuations

- Healthcare: KRW108,205.8bn (USD102.8bn) in 2014 to KRW114,321.2bn (USD103.9bn) in 2015;+5.7% in local currency terms and -4.9% in US dollar terms. Forecast broadly unchanged fromprevious quarter.

Table Of Contents

South Korea Pharmaceuticals and Healthcare Report Q1 2016
BMI Industry View ... 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (South Korea 2013-2019) . 7
SWOT 9
Industry Forecast .. 11
Pharmaceutical Market Forecast 11
Latest Updates .. 11
Structural Trend 12
Table: Pharmaceutical Sales, Historical Data And Forecasts (South Korea 2011-2019) . 13
Healthcare Market Forecast .. 14
Latest Updates ... 14
Structural Trends ... 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (South Korea 2011-2019) . 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (South Korea 2011-2019) . 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (South Korea 2011-2019) 16
Prescription Drug Market Forecast 17
Structural Trends ... 17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (South Korea 2011-2019) . 18
Patented Drug Market Forecast . 19
Structural Trends ... 19
Table: Patented Drug Market Indicators, Historical Data And Forecasts (South Korea 2011-2019) . 20
Generic Drug Market Forecast .. 20
Structural Trends ... 21
Table: Generic Drug Market Indicators, Historical Data And Forecasts (South Korea 2011-2019) . 22
South Korea ... 22
Structural Trends ... 23
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (South Korea 2011-2019) 25
Pharmaceutical Trade Forecast . 26
Structural Trends ... 26
Table: Pharmaceutical Trade Data And Forecasts (South Korea 2013-2019) 27
Table: Pharmaceutical Trade Data And Forecasts local currency (South Korea 2013-2019) 28
Industry Risk Reward Ratings .. 29
Asia Pacific Risk/Reward Index .. 29
South Korea Risk/Reward Ratings ... 36
Rewards ... 36
Risks 36
Regulatory Review 38
Regulatory Review . 38
Intellectual Property Issues .. 41
Pricing And Reimbursement Regime .. 43
Table: Different Price Control Levers 43
Market Overview ... 48
Market Overview ... 48
Healthcare System .. 48
Table: Healthcare Resources (South Korea 2009-2014) . 49
Table: Healthcare Personnel (South Korea 2009-2014) . 49
Table: Healthcare Activity (South Korea 2009-2014) 50
Healthcare Sector . 50
National Health Insurance Corporation . 51
Research And Development .. 53
Biotechnology Sector .. 54
Clinical Trials ... 56
Epidemiology 58
Competitive Landscape 61
Research-Based Industry . 61
Generic Drugmakers .. 62
Table: Multinational Market Activity . 64
Pharmaceutical Distribution 65
Pharmaceutical Retail Sector ... 66
Table: Pharmaceutical Retailers, 2000-10 . 67
Table: Timeline Of OTC Slow Liberalisation . 68
Company Profile 69
Daewoong Pharmaceutical 69
Dong-A Pharmaceutical ... 73
Eli Lilly . 78
GlaxoSmithKline . 81
Hanmi Pharmaceutical Co 84
Merck and Co 88
Novartis . 91
Pfizer 95
Sanofi 98
Yuhan Corporation 101
Demographic Forecast ... 105
Table: Population Headline Indicators (South Korea 1990-2025) 106
Table: Key Population Ratios (South Korea 1990-2025) . 106
Table: Urban/Rural Population and Life Expectancy (South Korea 1990-2025) . 107
Table: Population By Age Group (South Korea 1990-2025) 107
Table: Population By Age Group % (South Korea 1990-2025) . 108
Glossary ... 110
Methodology 112
Pharmaceutical Expenditure Forecast Model 112
Healthcare Expenditure Forecast Model ... 112
Notes On Methodology .. 113
Risk/Reward Index Methodology . 114
Index Overview 115
Table: Pharmaceutical Risk/Reward Index Indicators 115
Indicator Weightings 116

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.